ArticleJournal of the National Comprehensive Cancer Network : JNCCN2025
Potentially Inappropriate Medications, Frailty, and Outcomes in Patients With Cancer Managed in a National Health Care System.
Article in Journal of the National Comprehensive Cancer Network : JNCCN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPrevious studies have operationalized the NCCN list of high-risk medications in older adults into a measurable tool known as the Geriatric Oncology Potentially Inappropriate Medications (GO-PIMs) scale. The current study aims to evaluate the ability of GO-PIMs to identify high-risk medications and their impact on patients with both solid and liquid tumors managed in a large national health care system.
methodsWe performed a retrospective cohort study using data from the national Veterans Affairs (VA) Cancer Registry and electronic health records, including all veterans newly diagnosed with a solid or liquid malignancy from 2000 to 2022. The number of GO-PIMs for each patient was determined from outpatient pharmacy prescriptions filled in the 90 days preceding the initial cancer diagnosis (the index date). We assessed the association of PIMs with baseline frailty-measured using the electronic Veterans Affairs Frailty Index (VA-FI) and categorized as nonfrail (≤0.2), mildly frail (>0.2-0.3), or moderate-to-severely frail (>0.3)-and with unplanned hospitalization and mortality during follow-up, using multivariable models adjusted for age, gender, cancer type and stage, Charlson comorbidity index score, and socioeconomic factors.
resultsAmong 388,113 patients with newly diagnosed cancer (median age, 69.3 years [IQR, 62.8-76.7]; most common cancer types: prostate [21.5%], lung [23.7%], and gastrointestinal [20.5%]), GO-PIMs were prevalent, with 38% patients receiving ≥1 GO-PIM. Each additional GO-PIM was associated with a 66% increase in the odds of being mildly or moderate-to-severely frail at diagnosis, after adjusting for all covariates (ordinal regression adjusted odds ratio, 1.66; 95% CI, 1.65-1.67). Each additional GO-PIM was also associated with a higher hazard of unplanned hospitalization (Cox regression adjusted hazard ratio [aHR], 1.08; 95% CI, 1.07-1.08) and death (Cox regression aHR, 1.07; 95% CI, 1.06-1.07), after adjusting for frailty and all covariates.
conclusionsAn increasing number of PIMs, as identified by the GO-PIMs scale, was independently associated with greater risk of frailty at diagnosis, unplanned hospitalization during follow-up, and mortality among patients treated within a large national health care system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.